Revvity Inc. (RVTY) exhibits 45.0% gross margins and 3.1% return on invested capital within Health Care (Biotechnology: Laboratory Analytical Instruments), balanced against a 48.2x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 12.5% operating margin and 3.1% ROIC, outpacing sector cost of capital.
ROIC: 3.1% // GM: 45.0%YoY revenue trajectory of +3.7% paired with 2.75% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +3.7% // FCF YLD: 2.75%Altman Z-Score of 3.37 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.37 // F-SCORE: 7/9Trading at 76.7x trailing P/E (71.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 76.7x // EV/EBITDA: 48.2xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $157.00 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Laboratory Analytical Instruments require continuous execution to defend 8.4% net margins.
NET MARGIN: 8.4% // D/E: 0.36x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for RVTY & activate live FRED threshold breach alerts.